Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Astellas Pharma ( (JP:4503) ) is now available.
Astellas Pharma Inc. reported preliminary sales figures for its IZERVAY™ treatment for geographic atrophy secondary to age-related macular degeneration, totaling ¥15.9 billion or $110 million in the U.S. for the first quarter of FY2025. This announcement was made in conjunction with an investment community meeting, with further details to be discussed in the upcoming Q1 earnings call, highlighting the company’s ongoing efforts to strengthen its market position in ophthalmology.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas is a global life sciences company focused on providing transformative therapies in areas such as oncology, ophthalmology, urology, immunology, and women’s health. The company is dedicated to pioneering new healthcare solutions for diseases with high unmet medical needs through its research and development programs.
Average Trading Volume: 5,639,278
Technical Sentiment Signal: Sell
Current Market Cap: Yen2488.6B
For a thorough assessment of 4503 stock, go to TipRanks’ Stock Analysis page.